Page URL:

Cardiac stem cell study retracted over lack of reliability

18 March 2019
Appeared in BioNews 991

The Lancet has retracted a 2011 paper reporting clinical trial data using cardiac stem cells isolated by Dr Piero Anversa's former laboratory.

This is the latest update in a long-standing controversy regarding the reliability of the work produced under Dr Anversa's leadership while he was at Harvard Medical School in Boston, Massachusetts; 16 retractions have been issued thus far.

In 2014, the Lancet editors published an 'Expression of Concern' regarding the study on the Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO] trial. Now, upon further investigation the journal stated that 'the laboratory work undertaken by Piero Anversa and colleagues at Harvard cannot be held to be reliable', specifically referring to 'the data presented in figures 2 and 3 and in supplemental figures 2 and 3'.

These data refer to the validation of c-kit cells – the cardiac stem cell originally identified by the Anversa lab in 2003. Other research groups have historically questioned the validity of these cells and their regenerative potential (see BioNews 251), as several groups have failed to replicate the data generated by Dr Anversa and colleagues.

Last November, the US National Heart, Lung, and Blood Institute 'paused' a clinical trial for heart failure which used these c-kit cells (see BioNews 974), although it was assured that patient safety was not compromised as a result of participation.

A total of 31 retractions have currently been recommended by Harvard Medical School and Brigham and Women's Hospital, for the work produced by Dr Anversa, who closed his laboratory at the institutions in 2015.

For this latest retraction, the Lancet editors have specified that the clinical data produced by the collaborating author, Professor Roberto Bolli at the University of Louisville in Kentucky, was not in question. In an interview with The Scientist in 2015, Professor Bolli stressed that the data under scrutiny was produced by Dr Anversa's laboratory alone.

2 December 2019 - by Dr Rosie Morley 
Stem cell therapies may become redundant in repairing cardiac function after a heart attack, suggests a new study in mice...
5 November 2018 - by Shaoni Bhattacharya 
A US government agency has 'paused' a trial of stem cell treatment for heart failure following calls for 31 scientific papers to be retracted...
22 October 2018 - by Ruth Retassie 
Clinicians and researchers have petitioned that a clinical trial for a stem-cell based treatment for heart disease be halted, as some of the results on which it was based have been called into question...
12 November 2012 - by Dr Anna Cauldwell 
Eight heart attack patients given injections of stem cells harvested from their own hearts show significant improvement in their heart function two years after treatment...
25 March 2004 - by BioNews 
Two new studies have cast further doubt on the ability of blood stem cells to turn into heart cells, even though several clinical trials based on this promising new treatment are currently underway. Researchers at Stanford University, California, and the University of Washington in Seattle have failed to duplicate the...
2 April 2001 - by BioNews 
Two teams of scientists have made independent breakthroughs using stem cells to repair cardiac muscles damaged by heart attacks. They have shown in experiments on mice that heart muscle can repair after injections of stem cells. The stem cells used in the experiments were derived from the bone marrow of...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.